Cointime

Elpiscience Biopharmaceuticals

company

About

Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation cancer immunotherapies

  • 101 - 250

Highlights

Total Funding Amount
$260M
Funding Rounds
4
Investors
2

Details

Last Funding Type
Series C
Last Funding Money Raised
$105M
Industries
Biopharma,Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2017
Number Of Employee
101 - 250
Operating Status
Active

Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation cancer immunotherapies. The company has a robust pipeline of globally innovative molecules, covering wide range of targets in immuno-oncology. Founded and managed by a team of biopharma industry leaders and scientists, Elpiscience endeavors to advance at least one innovative molecule into the clinic each year to benefit cancer patients worldwide.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
4
$260M
Elpiscience Biopharmaceuticals has raised a total of $260M in funding over 2 rounds. Their latest funding was raised on May 13, 2021 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
May 13, 2021 Series C $105M 2 — — Detail
Dec 28, 2019 Series B $100M 1 — — Detail
Dec 3, 2018 Series A $35M 1 — — Detail
Apr 3, 2017 Series A $20M 1 Lilly Asia Ventures — Detail

Investors

Number of Lead Investors
Number of Investors
1
2
Elpiscience Biopharmaceuticals is funded by 2 investors. Superstring Capital and Lilly Asia Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Superstring Capital — Series C
Lilly Asia Ventures — Series C
Cointime
เนื้อหา
บริษัท